
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7124654/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel. Oncologist, 2022, 27, 4-6.	1.9	4
2	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	1.2	1
3	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923.	1.7	1
4	Clinical presentation and outcome of human papillomavirusâ€positive nasopharyngeal carcinoma in a North American cohort. Cancer, 2022, 128, 2908-2921.	2.0	10
5	A costâ€utility analysis comparing CT surveillance, PETâ€CT surveillance, and planned postradiation neck dissection for advanced nodal HPVâ€positive oropharyngeal cancer. Cancer, 2021, 127, 3372-3380.	2.0	5
6	Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. Cancers, 2021, 13, 3723.	1.7	5
7	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 682-695.	0.4	42
8	Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. Frontiers in Oncology, 2021, 11, 703995.	1.3	25
9	Examining the Landscape of Prognostic Factors and Clinical Outcomes for Cancer Control. Current Oncology, 2021, 28, 5155-5166.	0.9	0
10	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. International Journal of Radiation Oncology Biology Physics, 2020, 106, 134-145.	0.4	15
11	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	2.0	11
12	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVIDâ€19 pandemic: The Princess Margaret experience and proposal. Cancer, 2020, 126, 3426-3437.	2.0	42
13	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	1.6	46
14	Alpha Test of Intelligent Machine Learning in Staging Head and Neck Cancer. Journal of Clinical Oncology, 2020, 38, 1255-1257.	0.8	7
15	Global Consultation on Cancer Staging: promoting consistent understanding and use. Nature Reviews Clinical Oncology, 2019, 16, 763-771.	12.5	52
16	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. Oral Oncology, 2019, 97, 124-130.	0.8	2
17	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute, 2019, 111, 655-663.	3.0	56
18	Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma. Journal of Proteome Research, 2018, 17, 2045-2059.	1.8	65

#	Article	IF	CITATIONS
19	Reply to A. Levy et al. Journal of Clinical Oncology, 2018, 36, 2358-2359.	0.8	0
20	Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. Journal of Clinical Oncology, 2018, 36, 704-709.	0.8	155
21	Major Changes in Head and Neck Staging for 2018. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 505-514.	1.8	60
22	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. Cell Reports, 2018, 25, 1318-1331.e4.	2.9	56
23	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 340-352.	0.4	99
24	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncology, 2018, 4, 1073.	3.4	44
25	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 698-708.	0.4	48
26	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 71-79.	1.2	26
27	Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Current Treatment Options in Oncology, 2017, 18, 40.	1.3	455
28	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 368.	1.2	19
29	Impact of Type 2 Diabetes Mellitus on Survival in Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2017, 157, 657-663.	1.1	11
30	Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. Cmaj, 2017, 189, E1030-E1040.	0.9	40
31	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Investigational New Drugs, 2016, 34, 575-583.	1.2	9
32	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. Oral Oncology, 2016, 59, 43-49.	0.8	16
33	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1208.	1.2	20
34	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncology, 2016, 54, 75-80.	0.8	56
35	Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies. Radiotherapy and Oncology, 2016, 119, 14-21.	0.3	72
36	Human Papillomavirus Genotype Association With Survival in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2016, 2, 823.	3.4	98

#	Article	IF	CITATIONS
37	Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. Journal of Otolaryngology - Head and Neck Surgery, 2015, 44, 43.	0.9	37
38	Extra-pulmonary small cell carcinoma in the head and neck setting: The role of prophylactic cranial irradiation. Oral Oncology, 2015, 51, e57-e59.	0.8	5
39	Comparison of Health State Utility Measures in Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 696.	1.2	47
40	Current Status of Clinical Trials in Head and Neck Cancer 2014. Otolaryngology - Head and Neck Surgery, 2015, 152, 410-417.	1.1	8
41	External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta OncolA³gica, 2015, 54, 1423-1429.	0.8	195
42	CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology, 2015, 117, 83-90.	0.3	425
43	Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget, 2015, 6, 4537-4550.	0.8	50
44	Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. Oncotarget, 2015, 6, 39127-39139.	0.8	14
45	Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial. Radiotherapy and Oncology, 2014, 110, 165-171.	0.3	83
46	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology, 2014, 110, 172-181.	0.3	585
47	Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy. Radiotherapy and Oncology, 2014, 112, 308-313.	0.3	19
48	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncology, 2013, 49, 79-85.	0.8	239
49	Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. Journal of Clinical Oncology, 2013, 31, 543-550.	0.8	551
50	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiotherapy and Oncology, 2012, 103, 49-56.	0.3	167
51	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. Radiotherapy and Oncology, 2010, 95, 339-343.	0.3	105
52	Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology, 2010, 28, 2996-3001.	0.8	683
53	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. Journal of Clinical Oncology, 2009, 27, 6213-6221.	0.8	289
54	Techniques to modulate radiotherapy toxicity and outcome in soft tissue sarcoma. Current Treatment Options in Oncology, 2003, 4, 453-64.	1.3	23

#	Article	IF	CITATIONS
55	Recent advances in radiotherapy for soft-tissue sarcoma. Current Oncology Reports, 2003, 5, 274-281.	1.8	38
56	Preoperative Radiotherapy for Adult Head and Neck Soft Tissue Sarcoma: Assessment of Wound Complication Rates and Cancer Outcome in a Prospective Series. World Journal of Surgery, 2003, 27, 875-883.	0.8	59
57	Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Seminars in Radiation Oncology, 2003, 13, 274-289.	1.0	139